Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-CD70-CAR-IL-15-transduced cord blood-derived natural killer cells

A preparation of allogeneic, umbilical cord blood (CB)-derived natural killer cells (NKs) that have been engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human cluster of differentiation 70 (CD70) and interleukin-15 (IL-15), with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic anti-CD70-CAR-IL-15-transduced CB-derived NK cells target, bind to and induce selective cytotoxicity in CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27, is overexpressed on the surfaces of various cancer cell types. IL-15 is a pro-survival cytokine that promotes persistence of multiple lymphocyte lineages and potentiates the immune response against tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic anti-CD70-CAR-IL-15-expressing CB-NK cells
allogeneic anti-CD70-CAR-IL-15-transduced CB-derived NK cells
CAR.70-engineered IL15-transduced cord blood-derived NK cells
CAR.70/IL15-transduced CB-NK cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search